Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides

Details for Australian Patent Application No. 2012216487 (hide)

Owner Santaris Pharma A/S

Inventors Elmen, Joacim; Kearney, Phil; Kauppinen, Sakari

Agent FB Rice

Pub. Number AU-A-2012216487

Parent 2007234191

Filing date 28 August 2012

Wipo publication date 13 September 2012

International Classifications

A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose

A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/113 Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

A61P 3/06 Drugs for disorders of the metabolism

A61P 3/10 Drugs for disorders of the metabolism

A61P 9/10 Drugs for disorders of the cardiovascular system

A61P 31/14 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 Antineoplastic agents

Event Publications

13 September 2012 Application Open to Public Inspection

  Published as AU-A-2012216487

13 September 2012 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012216488-ANG-2 inhibition to treat multiple sclerosis

2012216486-Radio beacon and method for selectively communicating in accordance with 5.8 and 5.9 GHz DSRC standards